PSYC Announces Formation of Advisory Board

Company welcomes three leading voices from the medical, science, and psychotherapeutic sectors

LAS VEGAS, NV, Jan. 05, 2021 (GLOBE NEWSWIRE) -- (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) a digital media leader within the emerging sector of medicinal psychedelics, is pleased to announce the formation of the Company’s Advisory Board. Joining its newly established board is George Y. Salameh, MD, Hyder A. Khoja, PhD, and Kelli Foulkroud, MS, LPA, LPC, RYT. And as PSYC moves ahead with its growth within the emerging sectors of medicinal psychedelics and digital mental health, these advisors bring tremendous value to the Company through their collective knowledge and expertise.

“We are incredibly grateful and privileged to have the opportunity to welcome such a diverse and highly-skilled group of experts to our Advisory Board,” said David Flores, Chief Executive Officer of Global Trac Solutions, Inc. “As we move ahead into our next phase of growth, I recognize how important it is to surround our team with experts who have the ability to bring a perspective that is uniquely and beneficially derived from their many years of professional and personal experience. It is also quite encouraging that each of these experts share the passion we have here at PSYC for not only building a very successful business over the next several years but utilizing it to contribute to the betterment of humanity through a collective development and deployment of tools and resources intended to improve and optimize mental health and wellbeing.”

Dr. Salameh brings more than 35 years of experience within the medical community where he has served in the sectors of family and emergency practice and has held his California State Medical License since 1987. In addition to his extensive knowledge and experience as a physician, Dr. Salameh has also achieved success as an entrepreneur and as a real estate developer. He has also provided strategic consulting services for startup biotech and medical product companies in collaboration with San Diego venture capitalists for the past ten years.

Dr. Khoja has over 19 years of experience in the fields of molecular biology and genetic engineering and is an expert in translating ideas into action, including innovation, commercialization, and knowledge mobilization. His expertise in science and policy domains has led to a distinguished career in scientific research and business development with a passion for Molecular Biology and Genetic Engineering. Dr. Khoja leverages his knowledge in drug discoveries from plant extracts and analytics to validate consistent medical-grade plant nano-molecules for therapeutics. Dr. Khoja received his doctorate (Ph.D.), in 2003 with honors in Molecular Biology and Genetic Engineering from a French Ivy league: INP-ENSAT and had his Post-doctoral training from the Michigan State University a US land grant university. 

Kelli Foulkrod, MS, LPA, LPC, RYT has worked in the mental health field for over 19 years in a variety of academic and clinical settings. She is a transpersonal psychotherapist, trauma-informed yoga teacher, ceremonialist, and psychedelic integration therapist based in Austin, Texas, and is also licensed in Colorado. For the past ten years, she has managed her private practice, the , where she has focused her expertise and energy in supporting healing in trauma and complex PTSD, pregnant and postpartum women and their families, reproductive trauma, grief and loss, psychosis, bipolar, OCD, and treatment resistant depression.

Over the coming months, it is the Company’s intent to strategically add additional experts to its Advisory Board whom it believes may contribute to its continued growth and emergence as a leader within the sectors of medicinal psychedelics and digital mental health.

About Global Trac Solutions, Inc. (OTCPink: PSYC)

At Global Trac Solutions we are integrating media, creativity, and technology to develop and deploy thought-provoing ideas and solutions that are fostering and transforming the approach to some of society’s most pressing matters.

PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.

We believe in a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future. We truly are the right TRAC to follow.

Forward-Looking Statements Disclaimer:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors, including the effect of COVID-19, that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are disclosed on the OTC Markets.com website.

Disclaimer: Global Trac Solutions, Inc. does not in any way encourage or condone the use, purchase, sale or transfer of any illegal substances, nor do we encourage or condone partaking in any unlawful activities. We support a harm reduction approach for the purpose of education and promoting individual and public safety. If you are choosing to use psychedelic substances, please do so responsibly.

Corporate Contact:

Global Trac Solutions, Inc. (PSYC)



(702) 239-1919



OTCPINK: PSYC